EP0312581B1 — Pharmaceutical sustained release matrix and process
Assigned to Janssen Pharmaceuticals Inc · Expires 1993-03-10 · 33y expired
What this patent protects
An ibuprofen-sustained release tablet or tablet layer is formed by making a wet granulation using povidone (PVP) in alcohol as the granulating fluid which is mixed with ibuprofen ethylcellulose, a wicking agent e.g. microcrystalline cellulose, an erosion promoter e.g. pregelatini…
USPTO Abstract
An ibuprofen-sustained release tablet or tablet layer is formed by making a wet granulation using povidone (PVP) in alcohol as the granulating fluid which is mixed with ibuprofen ethylcellulose, a wicking agent e.g. microcrystalline cellulose, an erosion promoter e.g. pregelatinized starch, then drying and milling the granulation and blending with dry powdered erosion promotor, wicking agent, lubricant e.g. magnesium stearate and glidant e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a long-lasting slow and relatively regular incremental release of the ibuprofen.
Drugs covered by this patent
- Amoxil (amoxicillin) · Generic (originally Beecham/GSK)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.